The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
By 2030, What Market Size Is The Antibody Contract Manufacturing Market Expected To Reach Based On Its 2026 Value?
The antibody contract manufacturing market size has seen rapid expansion in recent years. It is forecast to rise from $16.79 billion in 2025 to $19.32 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 15.0%. The past growth can be attributed to several factors including an increase in biologics development pipelines, greater outsourcing by biopharmaceutical companies, the broadening of mammalian cell culture platforms, heightened clinical trial activity for antibodies, and the presence of specialized CMO infrastructure.
The antibody contract manufacturing market is anticipated to experience substantial expansion in the coming years, with its size projected to reach $34.72 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.8%. This growth throughout the forecast period is primarily fueled by the increasing demand for commercial-scale antibody production, greater investments in next-generation biologics, a heightened focus on cost-efficient manufacturing models, the broadening of personalized medicine pipelines, and an uptick in regulatory approvals for antibody therapies. Significant trends influencing this period encompass the expansion of large-scale antibody manufacturing capacity, the rising adoption of single-use bioprocessing systems, increasing demand for bispecific antibodies and ADCs, an intensified focus on flexible and scalable manufacturing models, and an enhanced emphasis on regulatory compliance and quality control.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Key Factors Are Driving The Antibody Contract Manufacturing Market Growth?
The growing count of clinical trials is anticipated to boost the expansion of the antibody contract manufacturing market moving forward. Clinical trials are investigative studies undertaken with human subjects to evaluate the safety and efficacy of novel medical treatments, interventions, or diagnostic protocols. As the volume of clinical trials involving antibody-based therapeutics or diagnostics rises, it generates a demand for premium quality antibodies, thereby ensuring a punctual and compliant supply for these trials. For instance, in May 2023, data from ClinicalTrials.gov, a component of the National Institutes of Health (NIH), a US-based government agency, indicated that the number of registered clinical trial studies across all 50 states of the United States and 221 countries escalated from 399,499 in 2022 to 437,533 in 2023. Additionally, about 241,498 studies, making up 53% of the total, were registered outside the United States, in contrast to 140,492 studies, or 31%, which were registered solely within the United States. Consequently, the increasing number of clinical trials is a primary force driving the growth of the antibody contract manufacturing market.
How Are Different Segments Classified In The Antibody Contract Manufacturing Market Segment Analysis?
The antibody contract manufacturing market covered in this report is segmented –
1) By Product: Monoclonal Antibodies, Polyclonal Antibodies, Other Products
2) By Source: Mammalian, Microbial
3) By Scale Of Operation: Preclinical, Clinical, Commercial
4) By End-User: Biopharmaceutical Companies, Research Laboratories, Other End Users
Subsegments:
1) By Monoclonal Antibodies: Therapeutic Monoclonal Antibodies, Diagnostic Monoclonal Antibodies
2) By Polyclonal Antibodies: Research Polyclonal Antibodies, Therapeutic Polyclonal Antibodies
3) By Other Products: Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Fusion Proteins
Which Trends Are Guiding The Direction Of The Antibody Contract Manufacturing Market?
Leading firms in the antibody contract manufacturing market are prioritizing breakthroughs like single-use technology, which serves to diminish cross-contamination hazards and lower operational expenditures. Single-use technology (SUT) describes components and systems that are disposable and utilized within biopharmaceutical production workflows. As an illustration, during September 2024, the US-based pharmaceutical entity Merck & Co. introduced the Mobius ADC Reactor, specifically engineered to improve the production of antibody-drug conjugates. This novel single-use reactor, tailored for antibody-drug conjugate manufacturing, substantially boosts production efficiency by 70% when contrasted with conventional stainless steel or glass techniques. Its disposable nature reduces the likelihood of cross-contamination and cuts down on operating expenses, thereby enabling quicker processing cycles. Furthermore, sophisticated film technology enhances the durability and leak resistance of the bags, safeguarding the quality of highly potent active pharmaceutical ingredients. Such advancements assist biopharmaceutical enterprises in manufacturing essential therapies with greater safety and efficiency.
Who Are The Companies Driving Activity In The Antibody Contract Manufacturing Market?
Major companies operating in the antibody contract manufacturing market are Lonza Group AG, Catalent Inc, Samsung Biologics Co Ltd, Wuxi Biologics Cayman Inc, Thermo Fisher Scientific Inc, Boehringer Ingelheim BioXcellence, AGC Biologics, FUJIFILM Diosynth Biotechnologies, AbbVie Inc, Charles River Laboratories International Inc, mAbxience, KBI Biopharma Inc, Abzena Ltd, Just-Evotec Biologics, Northway Biotech, Cerbios-Pharma, Scorpius BioManufacturing, Lotte Biologics, Rentschler Biopharma SE, Cytiva (Life Sciences CDMO), Xcellon Biologics, Celonic AG, Syngene International Ltd
Get The Full Antibody Contract Manufacturing Market Report:
Which Region Is The Largest In The Antibody Contract Manufacturing Market?
North America was the largest region in the antibody contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Antibody Contract Manufacturing Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Antibody Contract Manufacturing Market 2026, By The Business Research Company
Antibody Discovery Market Report 2026
https://www.thebusinessresearchcompany.com/report/antibody-discovery-global-market-report
Vaccine Contract Manufacturing Market Report 2026
Biopharmaceuticals Contract Manufacturing Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model